First Treatment for Anxiety in Alzheimer's Patients: U.S. Biotech Gains Revenue Growth Engine

Axsome Therapeutics, Inc. (AXSM) announced on April 30 that the U.S. Food and Drug Administration has approved an expanded indication for its drug Obvelity to include treatment of agitation associated with Alzheimer’s dementia. This supplemental new drug application (sNDA) approval was granted on the strength of Phase 3 ADVANCE-1 and ACCORD-2 trial data showing significant improvements in agitation symptoms and a longer time to relapse after response versus placebo. Building on its existing major depressive disorder indication, the company will immediately commercialize the new Alzheimer’s agitation use through its patient support program “Obvelity OnMySide” and is preparing for a full market launch in June.

In the first quarter of 2026, Axsome reported product net sales of $191.2 million—a 57% increase year-over-year—driven by Obvelity, Sunosi and Cymbrava. Despite this revenue growth, the company posted a net loss of $64.5 million. With $305.1 million in cash and cash equivalents, Axsome is advancing its central nervous system pipeline, including submission of an NDA for AXS-12 for cataplexy in narcolepsy, follow-on clinical studies for AXS-05 and solriamfetol, and development of AXS-20, a PDE10A inhibitor targeting schizophrenia and Tourette syndrome.

Immediately following the FDA announcement, Axsome’s shares jumped about 12% intraday. Several analysts have since raised their price targets or maintained buy ratings, citing expectations for a new revenue stream from the Alzheimer’s agitation indication. (wsau.com)

Axsome is a Nasdaq-listed U.S. biotech company focused on developing and commercializing therapies for central nervous system disorders such as depression, excessive daytime sleepiness and dementia-related behavioral symptoms. The company already markets Obvelity, Sunosi and Cymbrava and is expanding its indications and pipeline into areas including migraine and schizophrenia. Agitation in Alzheimer’s patients poses a significant burden on both patients and caregivers, and no effective approved treatments previously existed. Industry observers believe this oral therapy approval could open a multibillion-dollar market in CNS treatments. (barchart.com)